NCT05987163 - Study to Evaluate the Safety and Effectiveness of GP0116 | Biotech Hunter

Enrollment

186

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

October 29, 2024

Study Completion Date

March 31, 2026

Conditions

Skin Manifestations

Interventions

DEVICE

GP0116

GP0116 is an injectable, sterile, transparent product.

DEVICE

Active Comparator: FDA approved dermal filler device (RHA 3)

FDA approved dermal filler device (RHA 3)

Trial Locations (19)

10021

Galderma Investigational Site (Site#8658), New York

22209

Galderma Investigational Site (Site#7047), Arlington

27517

Galderma Investigational Site (Site#8482), Chapel Hill

28405

Galderma Investigational Site (Site#8648), Wilmington

30331

Galderma Investigational Site (Site#7042), Atlanta

33134

Galderma Investigational Site (Site#7030), Coral Gables

33146

Galderma Investigational Site (Site#8284), Coral Gables

33401

Galderma Investigational Site (Site#8126), West Palm Beach

34209

Galderma Investigational Site (Site#8479), Bradenton

37203

Galderma Investigational Site (Site#8496), Nashville

45236

Galderma Investigational Site (Site#8783), Cincinnati

48009

Galderma Investigational Site (Site#8631), Birmingham

70130

Galderma Investigational Site (Site#8580), New Orleans

77388

Galderma Investigational Site (Site#8662), Spring

90404

Galderma Investigational Site (Site#8074), Santa Monica

92083

Galderma Investigational Site (Site#8478), Vista

06880

Galderma Investigational Site (Site#8680), Westport

02467

Galderma Investigational Site (Site#8481), Chestnut Hill

00917

Galderma Investigational Site (Site#8784), San Juan